Creative Medical Technology Holdings, Inc.

$CELZ Market Cap: $4.247 Million

Research Board Inbox Deep Research Not Interested Shortlisted

Financial Snapshot

Revenue

$11.00K

TTM

Gross Margin

60.0%

TTM

Net Earnings

-$5.318M

TTM

Current Assets

$6.331M

Q3 2024

Current Liabilities

$330.9K

Q3 2024

Current Ratio

1913.35%

Q3 2024

Total Assets

$6.888M

Q3 2024

Total Liabilities

$330.9K

Q3 2024

Book Value

$6.557M

Q3 2024

Cash

$6.260M

Q3 2024

P/E

-0.7987

Nov 29, 2024 EST

Free Cash Flow

-$1.998M

TTM

Revenues

Revenue YoY Change

Revenues

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006
Revenue	$9.000K	$88.60K	$87.75K	$164.5K	$165.5K	$124.4K	$4.800K	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
YoY Change	-89.84%	0.96%	-46.65%	-0.6%	33.04%	2491.67%

Expenses

Cost Of Revenues

Gross Profit

Gross Profit Margin

Gross Profit

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006
Revenue	$9.000K	$88.60K	$87.75K	$164.5K	$165.5K	$124.4K	$4.800K	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Cost Of Revenue	$3.600K	$28.49K	$47.95K	$50.60K	$45.50K	$70.38K	$8.000K	$0.00
Gross Profit	$5.400K	$60.11K	$39.81K	$113.9K	$120.0K	$54.03K	-$3.200K	$0.00
Gross Profit Margin	60.0%	67.84%	45.36%	69.24%	72.51%	43.43%	-66.67%

Selling, General & Admin Expense

Research & Development

Depreciation, Depletion & Amortization

SGA Expense to Gross Profit Ratio

R&D To Gross Profit Ratio

DDA To Gross Profit Ratio

Operating Expenses Total

Operating Profits/Loss

Operational Expenses

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006
Selling, General & Admin	$3.560M	$3.944M	$2.964M	$1.162M	$1.223M	$1.050M	$898.5K	$665.0K	$20.83K	$20.00K	$20.00K	$20.00K	$20.00K	$10.00K	$30.00K	$50.00K	$10.00K	$0.00
YoY Change	-9.72%	33.03%	155.13%	-5.01%	16.44%	16.91%	35.12%	3092.41%	4.15%	0.0%	0.0%	0.0%	100.0%	-66.67%	-40.0%	400.0%
% of Gross Profit	65931.65%	6560.65%	7447.53%	1020.11%	1019.35%	1944.45%
Research & Development	$1.971M	$6.269M	$109.2K	$0.00	$0.00	$96.62K	$260.1K	$85.33K
YoY Change	-68.56%	5641.76%			-100.0%	-62.85%	204.78%
% of Gross Profit	36493.31%	10429.14%	274.29%	0.0%	0.0%	178.84%
Depreciation & Amortization	$94.58K	$92.08K	$92.08K	$66.79K	$26.95K	$21.14K	$16.00K	$9.360K
YoY Change	2.72%	0.0%	37.86%	147.83%	27.48%	32.13%	70.94%
% of Gross Profit	1751.48%	153.19%	231.33%	58.64%	22.46%	39.13%
Operating Expenses	$5.626M	$10.30M	$3.166M	$1.229M	$1.250M	$1.168M	$1.175M	$759.7K	$20.83K	$20.00K	$20.00K	$20.00K	$20.00K	$20.00K	$30.00K	$50.00K	$10.00K	$0.00
YoY Change	-45.41%	225.5%	157.64%	-1.71%	7.01%	-0.54%	54.62%	3547.02%	4.15%	0.0%	0.0%	0.0%	0.0%	-33.33%	-40.0%	400.0%
Operating Profit	-$5.620M	-$10.24M	-$3.126M	-$1.115M	-$1.130M	-$1.114M	-$1.178M	-$759.7K
YoY Change	-45.14%	227.72%	180.4%	-1.36%	1.43%	-5.4%	55.04%

Interest Expenses

Interest Expenses To Operating Income %

Other Expense/Income

Interest & Other Expense/Income

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006
Interest Expense	$333.6K	$0.00	$4.278M	$1.230M	-$6.987M	$1.361M	$377.6K	$6.398K	-$9.930K	-$10.00K	-$10.00K	-$10.00K	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
YoY Change		-100.0%	247.96%	-117.6%	-613.25%	260.56%	5801.64%	-164.43%	-0.7%	0.0%	0.0%
% of Operating Profit
Other Income/Expense, Net	$333.6K	$100.3K	$22.34M	-$35.21M		-$12.54M	-$1.481M	-$6.398K
YoY Change	232.47%	-99.55%	-163.44%			746.65%	23052.58%

Income/Loss

Pretax Income

Income Tax

Net Profits/Loss

Pretax Income YoY Change

Income Tax Rate

Net Profits/Loss YoY Change

Basic EPS

Net Income To Revenue Ratio

Pretax & Net Income

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006
Pretax Income	-$5.287M	-$10.14M	$19.21M	-$36.33M	-$8.484M	-$13.66M	-$2.659M	-$766.1K	-$30.76K	-$30.00K	-$30.00K	-$30.00K	-$20.00K	-$20.00K	-$30.00K	-$50.00K	-$10.00K	$0.00
YoY Change	-47.88%	-152.8%	-152.89%	328.18%	-37.87%	413.54%	247.11%	2390.47%	2.53%	0.0%	0.0%	50.0%	0.0%	-33.33%	-40.0%	400.0%
Income Tax	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
% Of Pretax Income			0.0%
Net Earnings	-$5.287M	-$10.14M	$19.21M	-$36.33M	-$8.484M	-$13.66M	-$2.659M	-$766.1K	-$30.76K	-$30.00K	-$30.00K	-$30.00K	-$20.00K	-$20.00K	-$30.00K	-$50.00K	-$10.00K	$0.00
YoY Change	-47.88%	-152.8%	-152.89%	328.18%	-37.87%	413.54%	247.11%	2390.48%	2.53%	0.0%	0.0%	50.0%	0.0%	-33.33%	-40.0%	400.0%
Net Earnings / Revenue	-58739.71%	-11449.26%	21892.75%	-22082.21%	-5126.08%	-10977.21%	-55398.08%
Basic Earnings Per Share		-$0.93	$7.37	-$62.69
Diluted Earnings Per Share	-$3.76	-$0.93	$5.61	-$62.69	-$410.0M	-$1.746B	-$1.873B	-$612.9M	-$254.6K	-$1.159K	-$1.129K	-$1.059K	-$995.50	-$714.10	-$1.308K	-$2.239K	-$1.076K	$0.00

Assets & Liabilities

Cash & Short-Term Investments

Cash & Equivalents

Cash To Operating Expenses Ratio

Inventory

Receivables

Total Short-Term Assets

Property, Plant And Equipment

Long-Term Investments

Total Long-Term Assets

Total Assets

Net Income To Total Assets Percentage

Accounts Payable

Short-Term Debt

Long Term Debt Due

Total Short-Term Liabilities

Long-Term Debt

Other Long-Term Liabilities

Total Long-Term Liabilities

Total Liabilities

Short-Term To Long-Term Debt Ratio

Short-Term Assets To Debt Ratio

Long-Term Debt To Net Income Ratio

Assets & Liabilities

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006
Cash & Short-Term Investments	$9.987M	$8.321M	$10.72M	$98.01K	$88.65K	$304.1K	$13.70K	$221.9K	$100.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$20.00K	$0.00
YoY Change	20.03%	-22.41%	10841.61%	10.56%	-70.84%	2119.42%	-93.83%	221770.0%								-100.0%
Cash & Equivalents
Short-Term Investments	$6.520M
Other Short-Term Assets	$277.3K	$10.42M									$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$10.00K	$0.00
YoY Change	-97.34%															-100.0%
Inventory	$6.590K	$10.19K	$10.87K
Prepaid Expenses
Receivables		$0.00	$2.490K	$0.00	$5.600K	$9.600K	$4.800K
Other Receivables		$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Total Short-Term Assets	$10.27M	$18.75M	$10.74M	$98.01K	$94.25K	$313.7K	$18.50K	$221.9K	$49.60K	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$40.00K	$30.00K
YoY Change	-45.21%	74.6%	10855.23%	3.99%	-69.95%	1595.46%	-91.66%	347.32%								-100.0%	33.33%
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$3.280K	$3.280K	$3.280K
YoY Change	0.0%	0.0%
Total Long-Term Assets	$444.3K	$438.9K	$531.0K	$619.8K	$436.6K	$163.5K	$184.7K	$100.6K	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
YoY Change	1.23%	-17.34%	-14.33%	41.97%	167.0%	-11.45%	83.48%
Total Assets	$10.72M	$19.19M	$11.27M	$717.8K	$530.8K	$477.2K	$203.2K	$322.5K	$49.60K	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$40.00K	$30.00K
YoY Change
Accounts Payable	$317.3K	$3.268M	$761.9K	$350.9K	$320.8K	$331.8K	$237.6K	$66.39K	$0.00	$10.00K	$10.00K	$10.00K	$10.00K	$0.00	$0.00	$0.00	$10.00K	$10.00K
YoY Change	-90.29%	328.89%	117.12%	9.39%	-3.33%	39.68%	257.84%		-100.0%	0.0%	0.0%	0.0%				-100.0%	0.0%
Accrued Expenses	$39.92K	$39.92K	$24.39K	$159.8K	$120.5K	$21.64K	$23.14K	$4.880K	$0.00
YoY Change	0.0%	63.67%	-84.73%	32.6%	456.79%	-6.48%	374.18%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00	$788.7K	$1.062M	$0.00	$250.0K	$100.0K	$100.00	$140.0K	$120.0K	$90.00K	$70.00K	$50.00K	$30.00K	$0.00	$0.00	$0.00
YoY Change			-100.0%	-25.75%		-100.0%	150.0%	99900.0%	-99.93%	16.67%	33.33%	28.57%	40.0%	66.67%
Long-Term Debt Due						$682.1K	$251.7K
YoY Change						170.93%
Total Short-Term Liabilities	$371.4K	$3.322M	$1.050M	$40.52M	$8.602M	$4.472M	$2.435M	$453.9K	$100.00	$150.0K	$130.0K	$100.0K	$80.00K	$50.00K	$30.00K	$0.00	$10.00K	$10.00K
YoY Change	-88.82%	216.22%	-97.41%	371.05%	92.37%	83.63%	436.55%	453760.0%	-99.93%	15.38%	30.0%	25.0%	60.0%	66.67%		-100.0%	0.0%
Long-Term Debt	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$920.00	$25.00K	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
YoY Change						-100.0%	-96.32%
Other Long-Term Liabilities						$0.00	$3.210K	$1.440K
YoY Change						-100.0%	122.92%
Total Long-Term Liabilities	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$4.130K	$26.44K	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
YoY Change						-100.0%	-84.38%
Total Liabilities	$371.4K	$3.322M	$1.050M	$40.52M	$8.602M	$4.472M	$2.439M	$480.3K	$100.00	$150.0K	$130.0K	$100.0K	$80.00K	$50.00K	$30.00K	$0.00	$10.00K	$10.00K
YoY Change	-88.82%	216.22%	-97.41%	371.05%	92.37%	83.32%	407.87%	480200.0%	-99.93%	15.38%	30.0%	25.0%	60.0%	66.67%		-100.0%	0.0%

Ownership

Basic Shares Outstanding

Diluted Shares Outstanding

Preferred Stock

Treasury Stock Shares

Stock Issuance & Repurchase

Ownership Data

Concept	2022	2021	2020	2015	2013	2012
Basic Shares Outstanding	10.93M shares	2.605M shares	579.5K shares	18.11M shares	18.11M shares	18.11M shares
Diluted Shares Outstanding	10.93M shares	3.249M shares
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Book Value

Free Cash Flow

Free Cash Flow YoY

Free Cash Flow Margin

Dividends

Stock Price

Market Cap: $4.2472 Million

About CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.

Creative Medical Technology Holdings, Inc. is a commercial stage biotechnology company which focuses on immunology, urology, neurology and orthopedics using adult stem cell treatments and interrelated regenerative technologies for the treatment of multiple indications. The company is headquartered in Phoenix, Arizona and currently employs 4 full-time employees. The company went IPO on 2009-05-01. The firm conducts substantially all of its commercial operations through its subsidiary, Creative Medical Technologies, Inc. Its products include AlloStem (CELZ-201-DDT) - allogenic human perinatal tissue derived cell program (clinical phase), ImmCelz (CELZ-100) - personalized supercharged immune therapy platform (pre-clinical trials), Type I Diabetes (CELZ-201 CREATE-1) - type I diabetes, Allostemspine Chronic Lower Back Pain (CELZ 201 ADAPT), Alova, CaverStem - erectile dysfunction treatment, FemCelz - female sexual function treatment, StemSpine - regenerative stem cell procedure for the treatment of degenerative disc disease (clinical trials), and OvaStem - stem cell therapy for premature ovarian failure.

Industry: Biological Products, (No Diagnostic Substances) Peers: Acorda Therapeutics, Inc. Aditxt, Inc. Panbela Therapeutics, Inc. CONTRAFECT Corp NUTRA PHARMA CORP MANHATTAN SCIENTIFICS INC REVELATION BIOSCIENCES, INC. Dogwood Therapeutics, Inc.